Ajan Reginald’s Post

🧬 European Life Sciences deals overview for 2023 & 2024 outlook 📈 https://lnkd.in/dsiQ5NpB Excited to share our latest publication. In this report, we delve into the dynamic landscape of life sciences investments across European targets, highlighting key trends across each deal type, notable deals, and emerging opportunities shaping the industry Explore the full report to stay informed and gain strategic perspectives on the future of life sciences investments in Europe #LifeSciences #Biotech #Investments

#ICYMI Value investor David Einhorn of Greenlight Capital and owner of over 1.27 million shares of Coya Therapeutics per quarter end 2023 13F filings, presented this week at Sohn Investment Conference on Wednesday. $COYA "It's a great time to be a value investor. There is less competition and plenty of cheap stocks, that are cheaper than they otherwise would be if there were more analysts around to sniff them out." #als #alzheimers #parkinsons #neurodegenerative #drugdiscovery #valueinvesting https://lnkd.in/dFc4Bwci

📈 Is the ASX on the cusp of a biotech boom? Rory Hunter, portfolio manager of SG Hiscock's Medical Technology Fund, thinks so, with some analysts suggesting CSL could get to $500. Read about Rory's outlook here 👉🏻 https://bit.ly/3XmOnaR #sghiscock #fundsmanagement #medicaltechnology #emergingmarkets The above is for information purposes only and does not constitute financial advice. Past performance is not an indication of future performance. We strongly recommend you conduct your own research prior to making investment decisions.

The Pengana High Conviction Equities Fund is committed to backing innovative, disruptive technologies that are shaping a better future. Over the past 12 months, the Fund has delivered an impressive 94% return.* A special congratulations to IperionX, Opthea, and Clarity Pharmaceuticals for their outstanding recent performances. Join Portfolio Manager James McDonald for an insightful webinar as he discusses the Fund’s current holdings, the key drivers behind its outstanding performance, and the evolving market dynamics that are guiding future strategies. This Global High Conviction Stocks Webinar is part of our 'Fund Focus Webinar Series.' You can secure your spot and explore other upcoming fund-focused webinars here: https://hubs.li/Q02PNjRp0 #healthcarestocks #biotechcompanies #Pharmaceuticals #fundperformance #returns #managedfunds #investing #webinar *As at 31 August 2024. Net performance figures are shown are those of Class A Units, after all fees and expenses, and assume reinvestment of distributions. No allowance has been made for buy/sell spreads. Please refer to the PDS for information regarding risks. Past performance is not a reliable indicator of future performance, the value of investments can go up and down. Inception 11 December 2014.

#ICYMI Value investor David Einhorn of Greenlight Capital and owner of 588,410 shares of Gain Therapeutics per quarter end 2023 13F filings, presented this week at Sohn Investment Conference on Wednesday. $GANX "It's a great time to be a value investor. There is less competition and plenty of cheap stocks, that are cheaper than they otherwise would be if there were more analysts around to sniff them out." #parkinsons #neurodegeneration #alzheimers #drugdiscovery #valueinvesting https://lnkd.in/dFc4Bwci

As development cost and complexity continue to increase, it is more important than ever for biotech to be more intentional with the deployment of the funds they secure. In part two of our biotech funding whitepaper series, we share practical considerations to improve asset development programs across operational strategies, acceleration, regulatory, value-building and partnership aspects. https://ow.ly/uyH350RrYLy

The healthcare industry is at a critical tipping point. At GE HealthCare, we are focused on delivering on a future of healthcare that will be personalized and preventive, with better patient outcomes at lower costs. Watch the latest episode of Nasdaq and Invesco QQQ’s Innovation Answered series to hear our CFO Jay Saccaro 😊 discuss the role @GEHC is playing in healthcare innovation. #GEHealthCare #FutureofHealthcare #AI #PrecisionCare

VC investment in biopharma is on the rise in the US, with Q2 2024 showing significant growth over Q1 and the previous year, according to Evaluate Pharma. Great insights by Mandy Jackson! #Biopharma #VentureCapital #InvestmentTrends

It was great to catch up with Alex Stella, MD of InvestorHub this week. The company is doing something we have long championed - making the IR function of a company a value centre rather than a cost centre. There is increasing interest from #ASX and global investors in the Frankfurt Stock Exchange and using a home country listing to reach a global investor market, through a dual listing such as on Börse Frankfurt. We also argue working closely with professionals on the ground with local knowledge, skills and contacts is also vital. InvestorHub is now used by ASX companies such as Recce Pharmaceuticals Ltd, Race Oncology and Emyria (ASX:EMD) and should be well placed to capture a large share of the market. #investorrelations #capitalmarkets #globalstrategy #bourse #equities #finance #europeanmarkets

🧠 💰 Smart Financial Moves for Life Sciences Pioneers 🙏 A big thank you to Jody Staggs from SWK Holdings Corporation for the insights in: "Five Financial Strategies Life Sciences Companies Should Consider" 🔍 The article captures the importance of balancing innovation with financial prudence by: 1️⃣ diversifying funding sources 2️⃣ exploring alternative finance structures like royalty financing, and; 3️⃣ prioritising key clinical milestones 💡 A standout point for us, in relation to vendor management and oversight for clinical development, is the emphasis on prioritising key clinical milestones. This approach is crucial for guiding strategic partnerships and maintaining focused, goal-oriented collaborations. It underscores the importance of strategic decision-making in funding and operational management to drive clinical objectives. 🔗 See full article here: https://lnkd.in/eEPBpT5t #lifesciences #clinicaldevelopment #financestrategy #risk #pharma #biotech #clinicaltrials